Thrombosis and Hemostasis Summit of North America (THSNA)
Hyatt Regency Chicago
151 East Wacker Service Dr Chicago, IL 60601, United States (312) 565-1234
Chicago, illinois
Three days of the summit are focused on the most current issues in hemostasis and thrombosis. THSNA will include daily general sessions (without other concurrent sessions); three educational tracks, a clinical pre-conference, poster sessions, oral abstract presentations of original research, and meet the experts programs. The color-coded key below distinguishes between the general sessions, three educational tracks and exhibit/networking opportunities
THSNA will highlight basic science, clinical, and laboratory information that reflects the latest understanding of common hemorrhagic and thrombotic disorders. THSNA will
    Provide evidence-based content focused on thrombosis and hemostasis
    Present cutting edge research
    Integrate the entire multi-disciplinary team
    Establish a channel for the next generation of clinicians and allied health professionals
    Highlight best practices in clinical management
    Drive multi-disciplinary professional networking opportunities
    Advocate for improved patient care and research funding
At the conclusion of THSNA, participants should be able to:

Thrombosis: Describe best practices and strategies used for the diagnosis, prevention and treatment of thromboembolic disease.

    Report on new drugs to prevent stroke for patients with atrial fibrillation or mechanical heart valves.
    Describe the approaches to rapid reversal of new antithrombotic agents.
    Describe the appropriate duration for treatment of venous thromboembolism and ways to predict recurrence.
    Describe the appropriate transition of care for hospital patients on new anticoagulants.
    Discuss the significant links between cancer and coagulation and the impact of anticoagulant treatment on cancer outcome.
    Review the advances and limitations of the new oral anticoagulants.
    Discuss the clinical implications of the changes in the ACCP guidelines.
    Identify the changes in the most recent ACCP guidelines regarding antithrombotic therapy.
    Review the risks and benefits of non-traditional approaches to the prevention and treatment of VTE.
    Recognize the diagnosis and treatment of patients with HIT.
    Review evaluation and treatment options for children with venous thromboembolism.
    Discuss the management of thrombophilic pregnancies.
    Discuss the challenging issues of hormone-related thrombosis.
    Describe the thought process involved in making clinical decisions for challenging clinical cases.

Hemostasis: Describe best practices and strategies used for the diagnosis, prevention and treatment of hemostasis.

    Report on the critical research in the diagnosis and management of patients with congenital or acquired inhibitors.
    Summarize the clinical and laboratory implications of the recent von Willebrand Disease trials.
    Examine the diagnosis and management of rare bleeding disorders.
    Explain how blood products and plasma derivatives can help the patient with life threatening hemorrhage.
    Review the role of splenectomy in managing ITP.
    Review challenges and treatment options in the care of aging patients with hemophilia.
    Discuss emerging therapies for TTP.
    Discuss best-practice approaches to treating pediatric patients with bleeding disorders.
    Discuss the emerging role of using TPO-mimetic agents sooner than later in ITP care.
    Discuss the management and complications of postpartum hemorrhage.
    Examine the new long acting agents for hemophilia.
    Incorporate successful intervention strategies to manage adolescent transition.

Laboratory: Describe new laboratory diagnostic techniques for the diagnosis and management of thrombotic and bleeding disorders.

    Describe new diagnostic techniques for evaluating hemostasis.
    Describe the laboratory evaluation of antibody mediated bleeding disorders.
    Describe the pathophysiology and treatment of patients with the antiphospholipid syndrome.
    Discuss the discrepancy between the PTT and chromogenic FVIII in mild hemophilia.
    Explain the improvements in testing for thrombophilias.
    Explain the clinical utility of the different laboratory assays for bleeding disorders
The conference is being held May 3-5, 2012 at the Hyatt Regency Chicago. The AAA Four Diamond Hyatt Regency Chicago is conveniently connected to the Illinois Center and within minutes of the Magnificent Mile. Sway to the electrified beat of Chicago blues and jazz greats, take in a show at Navy Pier, shop on Michigan Avenue, or enjoy a day in the park or on the water. The cosmopolitan downtown Chicago, Illinois hotel is central to it all. To reserve a room at the discounted group rate

Schedule of Presentations:

Thursday, May 3, 2012
09:00:00 Registration
09:05:00 Clinical Practice Pre-Conference Adolescent Transition: Engaging Young Adults with Chronic Disease Susan Fernandes
10:00:00 Adolescent Transition in Hemophilia and Cardiology/Anticoagulation: Case Studies Susan Fernandes
12:45:00 Welcome David Garcia, Peter A. Kouides
13:00:00 General Session 1 | Common Bleeding & Thrombotic Disorders: State of the Art Stephan Moll
13:30:00 von Willebrand Disease: Clinical and Laboratory Lessons Learned from the Large vWD Studies David Lillicrap
14:00:00 Cancer and Coagulation Alok Khorana
14:05:00 Managing ITP, the Old and the New
14:15:00 a. Splenectomy Earlier then Later
14:20:00 b. The TPO-mimetic Agents Earlier then Later Terry Gernsheimer
14:30:00 Q&A
15:00:00 Afternoon Break
15:30:00 The Aging Patient with Hemophilia Barbara Konkle
15:30:00 What’s New in the ACCP Guidelines (and Why?) David Garcia, Mark Crowther
15:30:00 Advances in Laboratory Testing: Thrombophilias Betsy Van Cott
16:30:00 TTP – New Insights, New Therapies Dave Motto
16:30:00 Advances in Laboratory Testing: Evaluation of Hemostasis in Flowing Blood Eric F. Grabowski
16:30:00 ACCP Guidelines Panel Discussion Scott Kaatz, Mark Crowther, Lynn Oertel, Daniel Witt, Ann Wittkowsky
17:30:00 Welcome Reception
Friday, May 4, 2012
07:00:00 Registration
07:05:00 Networking Continental Breakfast
07:45:00 General Session 2 - Oral Abstract Presentations Eric F. Grabowski
08:45:00 Break
09:00:00 Blood Product Support in Coagulopathic Conditions: Is There a Method to the Madness? Ravi Sarode
09:00:00 Predicting the Risk of VTE Recurrence John A. Heit
09:45:00 “Rare” Bleeding Disorders: Fine Points of Diagnosis and Management, a Career Perspective Diane Nugent
09:45:00 Interventional Approaches to VTE Suresh Vedantham
10:25:00 Break
10:55:00 General Session 3 - The Future of Anticoagulation Jack Ansell
11:15:00 1. The View from the Lab Jeffrey Weitz
11:30:00 2. Stroke Prevention in AF and Mechanical Heart Valves John Eikelboom
11:45:00 3. Lab Monitoring of Anticoagulation Rajiv K. Pruthi
12:00:00 Reversal of Antithrombotic Agents KENNETH A. BAUER
12:15:00 Q&A
12:45:00 Lunch Break – Nursing Round Tables
14:00:00 Antibody Mediated Bleeding Disorders Jim Zehnder
14:00:00 Length of VTE Treatment & Drug Choices in Chi Bryce Kerlin
14:45:00 The Hope and Reality of the Long Acting New Agents for Hemophilia Steven W. Pipe
14:45:00 Inpatient Transition of New Anticoagulants Geno Merli
14:45:00 Antiphospholipid Syndrome
15:35:00 HITlights… a Career Perspective Ted Warkentin
15:35:00 Diagnosis and Management of Inhibitors: 5 Papers That Should Change Your Practice Cindy Leissinger
15:50:00 An Update in Pediatric Bleeding Disorders
16:00:00 Poster Session
Saturday, May 5, 2012
07:30:00 Meet the Expert Breakfast
08:00:00 Registration
08:15:00 Laboratory Investigations of Bleeding Disorders
08:15:00 Treating the Female Patient
08:45:00 1. Approaches to Investigating Common Bleeding Disorders Cathy Hayward
08:45:00 1. Pregnancy and Thrombophilia: Thrombosis & Other AdverseEvents Michael Paidas
09:15:00 Postpartum Hemorrhage - When Uterotonics and Sutures Fail
09:20:00 2. Inherited Coagulopathies Rajiv K. Pruthi
09:40:00 Oral Contraceptives, Hormone Replacement, and Anticoagulation
09:45:00 Q&A
09:45:00 3. Acquired Coagulopathies Ravi Sarode
09:50:00 Stop the Clot Forum – Patient Session
09:55:00 Q&A
10:00:00 Morning Break
10:30:00 General Session 5 – Di"cult Cases Panel Stephan Moll, David Garcia, James B. Bussel, Christine Guelcher, Scott Kaatz
12:15:00 Closing Remarks
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.